第636回日本泌尿器科学会東京地方会　ベストプレゼンテーション賞
廣瀬 航平, 福田 翔平, 大川 紗由里, 木村 浩一朗, 中村 祐基, 内田 裕將, 上原 翔, 田中 一, 吉田 宗一郎, 横山 みなと, 岸野 充浩, 松岡 陽, 立石 宇貴秀, 藤井 靖久. 経皮的腎瘻造設術後の腎仮性動脈瘤に対して経カテーテル動脈塞栓術による止血を要した局所進行膀胱癌の1例. 第636日本泌尿器科学会東京地方会 2020年9月16日

Fukushima H, Moriyama S, Waseda Y, Fukuda S, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 7(2):366-372, 2021.PubMed

Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer. 19(3):208-216, 2021.PubMed

Cotta BH, Meagher MF, Patil D, Saito K, Patel SH, Patel DN, Miller N, Dutt R, Keiner C, Bradshaw AW, Wan F, Eldefrawy A, Yasuda Y, Fujii Y, Master V, Derweesh IH. Elevated Pre-operative C-reactive Protein Is Associated with Renal Functional Decline and Non-Cancer Mortality in Surgically Treated Renal Cell Carcinoma: Analysis from the INternational Marker Consortium for Renal Cancer [INMARC]. BJU Int. 127(3):311-317, 2021.PubMed

Waseda Y, Yoshida S, Arita Y, Takahara T, Sakamoto T, Saito K, Fujii Y. Potential of Perfusion Magnetic Resonance Imaging to Predict Residual Renal Function after Radical Nephroureterectomy. Urol Int. 105(5-6):507-513. 2021.PubMed

Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. Mar;70(3):657-665, 2021.　PubMed

Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Yokoyama M, Fujii Y. Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems. Int J Urol. 28(1):127-129, 2021.PubMed

Yoshida S, Takahara T, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer? Int J Urol. 28(2):241-242, 2021.PubMed

Yasuda Y, Saito K, Tanaka H, Uehara S, Kijima T, Yoshida S, Yokoyama M, Matsuoka Y, Kihara K, Fujii Y. Outcomes of gasless laparoendoscopic single-port partial nephrectomy in 356 consecutive patients: Feasibility of a clampless and sutureless technique. Int J Urol. 28(3):302-307, 2021.PubMed

Yoshida S, Matsushima H, Fujii Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. World J Urol. doi: 10.1007/s00345-020-03570-9. 2021.PubMed

Fukushima H, Yoshida S, Kijima T, Nakamura Y, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yokoyama M, Matsuoka Y, Fujii Y. Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. Int J Mol Sci. 22(2):535, 2021.PubMed

Yoshida S, Takahara T, Arita Y, Toda K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy. Int Urol Nephrol. 53(6):1119-1125, 2021.PubMed

Arita Y, Yoshida S, Waseda Y, Takahara T, Ishii C, Ueda R, Kwee TC, Miyahira K, Ishii R, Okuda S, Jinzaki M, Fujii Y. Diagnostic value of computed high b-value whole-body diffusion-weighted imaging for primary prostate cancer. Eur J Radiol. 137:109581, 2021.PubMed

Fukuda S, Saito K, Yasuda Y, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Kageyama Y, Fujii Y. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 9(2):e001564, 2021.PubMed

Yamamoto S, Yoshida S, Ishii C, Takahara T, Arita Y, Fukushima H, Tanaka H, Yokoyama M, Matsuoka Y, Fujii Y. Metastatic Diffusion Volume Based on Apparent Diffusion Coefficient as a Prognostic Factor in Castration-Resistant Prostate Cancer. J Magn Reson Imaging. 54(2):401-408, 2021.PubMed

Patel SH, Derweesh IH, Saito K, Patil D, Meagher MF, Bindayi A, Eldefrawy A, Patel DN, Nasseri R, Yasuda Y, Fujii Y, Master VA. Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC). Clin Genitourin Cancer. 19(4):e206-e215, 2021.PubMed

Saito K, Matsuoka Y, Toda K, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. Brachytherapy. 20(4):842-848., 2021.PubMed

Fujiwara M, Tanaka H, Yuasa T, Komai Y, Oguchi T, Fujiwara R, Numao N, Yamamoto S, Fujii Y, Fukui I, Yonese J. First-line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice. Int J Urol. 28(9):920-926, 2021.PubMed

Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. Eur Radiol. 32(1):671-679, 2021.PubMed

Maruyama R, Fukushima H, Fukuda S, Yasuda Y, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Kihara K, Fujii Y. Nonuse of antimicrobial prophylaxis in clean surgeries for adrenal and renal tumors: Results of the risk-based strategy in 1362 consecutive patients. Int J Urol. 28(10):1032-1038, 2021.PubMed

Yoshida S, Matsuoka Y, Toda K, Uehara S, Tanaka H, Yokoyama M, Saito K, Yoshimura R, Fujii Y. Nonmetastatic castration-resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy. IJU Case Rep. 4(4):228-230, 2021.PubMed

Kobayashi M, Ishioka J, Matsuoka Y, Fukuda Y, Kohno Y, Kawano K, Morimoto S, Muta R, Fujiwara M, Kawamura N, Okuno T, Yoshida S, Yokoyama M, Suda R, Saiki R, Suzuki K, Kumazawa I, Fujii Y. Computer-aided diagnosis with a convolutional neural network algorithm for automated detection of urinary tract stones on plain X-ray. BMC Urol. 21(1):102, 2021.PubMed

Arita Y, Yoshida S, Kwee TC, Akita H, Okuda S, Iwaita Y, Mukai K, Matsumoto S, Ueda R, Ishii R, Mizuno R, Fujii Y, Oya M, Jinzaki M. Diagnostic value of texture analysis of apparent diffusion coefficient maps for differentiating fat-poor angiomyolipoma from non-clear-cell renal cell carcinoma. Eur J Radiol. 143:109895, 2021.PubMed

Shimada W, Tanaka H, Fukawa Y, Kimura K, Yamamoto K, Fukuda S, Fukushima H, Yasuda Y, Uehara S, Yoshida S, Yokoyama M, Matsuoka Y, Tateishi U, Campbell SC, Fujii Y. Infiltrative tumor interface with normal renal parenchyma in locally advanced renal cell carcinoma: Clinical relevance and pathological implications. Int J Urol. 28(12):1233-1239, 2021.PubMed

Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, Briganti A, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Rouprêt M, Masson-Lecomte A, Laukhtina E, D'Andrea D, Shariat SF, Soria F, Marra G, Gontero P, Contieri R, Hurle R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatte T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. Eur Urol Focus. S2405-4569(21)00195-4, 2021.PubMed

Yokoyama M, Ishioka J, Toba M, Fukushima H, Tanaka H, Yoshida S, Matsuoka Y, Ai M, Fushimi K, Fujii Y. Trends and safety of robot-assisted partial nephrectomy during the initial 2-year period after government approval in Japan: A nationwide database study from 2016 to 2018. Int J Urol. 28(12):1268-1272, 2021.PubMed

Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia Pac J Clin Oncol. doi: 10.1111/ajco.13666. 2021.PubMed

Yoshida S, Fujii Y. MRI-Targeted Biopsy in Prostate Cancer Screening. N Engl J Med. 385(22):2110, 2021.PubMed

Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol. S1078-1439(21)00505-6, 2021.PubMed

Yoshida S, Takahara T, Arita Y, Sakaino S, Katahira K, Fujii Y. Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond. Int J Urol. 28(5):502-513, 2021.PubMed